PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/612,391 Filing Date July 3, 2003 Harmut KUEPPERS et al. First Named Inventor Art Unit 1614 **Examiner Name** To be assigned Attorney Docket Number 029300.52512US

(use as many sheets as necessary) Sheet of

**U.S. PATENT DOCUMENTS** Examiner Cite Publication Date Document Number Name of Patentee or Pages, Columns, Lines, Where Relevant Passages or Relevant No.1 MM-DD-YYYY Applicant of Cited Document Number-Kind Code<sup>2</sup> (if known) Figures Appear US-US-US-US-บร-US-

		FOREIG	N PATENT DO	CUMENTS							
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Oocument  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>1</sup> (# known)	Publication Oate	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relavant Passages or Relevant Figures Appear	Τ*					
7	AA 7 : WO-97/49394-A2		12-31-1997	NOVARTIS AG	of Neiovalli Figures Appear	AB					
	AB ·	WO-01/15673-A2	03-08-2001	AVENTIS PHARMA DEUTSCHLAND GMBH		AB					
	AC -	WO-01/01987-A1	01-11-2001	ASTRAZENECA AB		AB					
	AD ·	WO-99/45779	09-16-1999	SMITHKLINE BEECHAM CORPORATION		AB					
	AE •	WO-99/00383	01-07-1999	SMITHKLINE BEECHAM CORPORATION		АВ					
Ž.	AF	WO-97/36874	10-09-1997	SMITHKLINE BEECHAM CORPORATION		AB					
		NON PATE	NT LITERATURE (	OCUMENTS	· · · · · · · · · · · · · · · · · · ·	•					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  SCHRADER, JOACHIM, et al., Preventing Stroke: High Risk Patients Should Receive Ramipril Irrespective of Their									
7		Blood Pressure, BMJ, Vol. 324, March 23, 2002, pp 687-689.									
	АН	SCHRADER, J. et al., Unawünschte Arzneimittelwirkungen und Weschselwirkungen von AT <sub>1</sub> -Rezeptörantogonisten, Medizinischen Hochschule Hanover, pp. 141-168.									
2	Al -	SCHRADER, J. Et al., Die Syst-Eur-Studie: Nutzeffeckt der Therapie der isolierten systolischen Hypertonie bei älteren Patlenten, Münch. Med. Wschr. 139, 1997, Nr. 7, MMV Medizin Verlag GmbH München, Germany, pp 693/35-696/38.									
	AJ	KOLLMANN; K., et al., tilittales Biutdruckverhalten von Patienten mit acuter zerobraler Ischamle; Extended Abetracts, pp 573-574.									
2	AK	SCHRADER, JOACHIM, Wenn nachts der Blutdruck nicht abfällt: Schlaganfall-Risiko massiv erhöht, MMW-Fortschr. Med, 2002, pp 55-56, Nr. 7.									
1	AL	KIRCHBERG, A. et al., Antihypertensive Therapie mit Kalziurnantagonisten und ACE-Hemmern bei Patienten nach zerebraler Ischämie, Nieren- und Hochdruckkrankheiten, Jahrgang 25, 1996, pp 385-387, Nr. 8.									
2	AM	LUEDERS, S., et al., Je höher desto früher: Hochdruck macht dement, MMW-Fortschr. Med, 2000, pp 42-44, Nr. 12.									

Substitute for form 1449A/PTO

Complete if Known

Application Number 10/612,391 INFORMATION DISCLOSURE Filing Date July 3, 2003 First Named Inventor Harmut KUEPPERS et al. STATEMENT BY APPLICANT Art Unit 1614 **Examiner Name** To be assigned Sheet Attomey Docket Number 029300.52512US of NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Initials\* No.1 journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. AN WITTE, M., et al., Antihypertensive Theraple mit ACE-Hemmern bei renoparenchymatoser Hypertonie mit und ohne nachtlichen Blutdruckabfall, Extended Abstracts, pp 580-581. No date AO SCHRADER, J., et al., Antihypertensive Therapie bei älteren Patienten, Münch. Med. Wschr. 138, 1996, pp 743/43-748/50. AΡ SCHRADER, J., et al., Antihypertensive Therapie bei älteren Patienten, Gustav Fischer Verlag Jena Z ärztl Fortbild (ZaeF), 1995, pp 825-832, Vol. 89. AQ BLÖMER, A., et al., Vergleichende Untersuchung der 24-Stunden-Blutdruckwirksamikeit der ACE-Hemmer Ramipril und Captopril bei Patienten mit essentieller Hypertonie; Nieren- und Hockdruckkrankheiten, Jahrgang 25, 1996, pp 392-394, Nr. 8. AR SCHRADER, J. et al., Bedeutund der 24-Stunden-Blutdruckmessung in der Dignostik und Therapie der arteriellen Hypertonie, Klin Wochenschr, (1990), pp 1119-1126, Nr. 68. AS SCHRADER, J. Et al., Blutdrucksenkung - so verhindern Sie vier von zehn Schlaganfällen: Antihypertensive Therapie vollstäng ausreizen, MMW-Fortschr. Med., 2000, pp 22-25, Nr. 1-2. ΔT SCHILLING, H. Et al., Was ist gesichert in der Therapie mit Konversionshemmern, Internist, 1987, pp 810-817, Nr. AU LÜDERS, S. et al., Führt der Eizatz der Lanzeitblut-druckmessung zu einer Reduzierten Anzahl von Antihypertensiva in einer Langzeitstudie? Prospektive, Random-siert 5-Jahres-Studie zum Vergleich von Prazis- und 24-Stunden-Blutdruckmessung bei hypertonikem, J Hyperton, 2001, pp 7-15, Nr. 1. ΑV LÜDERS, S. et al., Praxisblutdruckmessun versus Lanzeitbltdruckmessung unterder Therapie mit Ramipril: Erste Ergebnise einer Langzeitstudie, Nieren- und Hochdruckkrankheiten, Jahrgang 25, 1995, pp 118-120, Nr. 3. AW LÜDERS, S. et al., Kombinationstherapie von β-Blockern und ACE-Hemmern bei essentieller Hypertonie, Nierenund Hochdruckkrankheiten, Jahrgang 21, 1992, pp 677-679, Nr. 11. AX SCHRADER, J. et al., Zur einundzwanzigsten Folge: Hypertonie und Schlaganfall - ein risikoreiches Duo, MMW-Fortschr. Med., 2001, pp 1-12, Nr. 31-32. SCHRADER, JOACHIM et al., Akutohase des Schlaganfalls: Bluthochdruck senken oder nicht senken, MMW-AY Fortschr. Med., 2003, pp 41-42, Nr. 1-2. SCHRADER, JOACHIM et al., Bei arterieller Hypertonie: ACE-Hemmer und Kombinationstherapie, Pharm. Unserer AZ Zeit 32, 2003, pp 46-52, Nr. 1. BA KULSCHEWSKI, A. Et al., ACCESS-Studie: Blutdruckkontrolle mit Candesartan Cilexetii bei Patienten mit a cuter zerbraler Ischämie und Hypertonie, Nieren- und Hochdruckkrankheiten, Jahrgang 29, 2000, pp 618-619, Nr. 12. SCHRADER, J. et al., Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR BB Study): A Randomised, Prospective long-term study to evaluate the Benefits of ABPM in patients on Antihypertensive Treatment, Journal of Human Hypertension, 2000, pp 435-440, Nr. 14. BC FLASNOECKER, MONIKA, Interview: Dient Blutdrucksenkung auch der Prävention des Schlaganfalls, Fortschritte der Medizin 115, 1997, pp 49-50, Nr. 5. BD SCHRADER, J. et al., Hypertension and Stroke - Rational Behind the ACCESS Trial, Basic Res. Cardiol 93: Supp. 2, 1998, pp 69-78. BOSCH, JACKIE, et al., Use of Ramipril in Preventing Stroke: Double Blind randomized Trial, BMJ, Vol. 324, BE March 23, 2002, pp 699-702. Complete if Known Substitute for form 1449A/PTO

1/14/05

**INFORMATION DISCLOSURE** 

Application Number

First Named Inventor

Filing Date

10/612,391

July 3, 2003

Harmut KUEPPERS et al.

١

TATE	MENT BY API	PLICA	ANT		To be assigned RADEMAR				
		·							
3 of 3		<u> </u>		029300.52512US					
			NON PATE	ENT LITERATURE DOCUMENT	S				
BF	Hypertonle: PRO und KONTRA Fixe Kombinationstheraple, Fortschritte der Medizin 116, 1998, pp 37-38, Nr. 14.								
BG	SCHRADER, J. et al., ACE-Hemmer, Internist, 1992, pp 356-360, Nr. 33.								
ВН	SCHRADER, JOACHIM. et al., The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors, Stroke, July 2003, pp 1699-1703.								
ВІ	SCHRADER, J., Interview mit Studienleiter Prof. Joachim Schrader: Arbeitsplats-Hypertoniker gibt es deutlich mehr als erwartet  No Late								
	BF BG BH	BF Hypertonie: PRO  BG SCHRADER, J. 6  BH SCHRADER, JO Survivors, Stroke	BF Hypertonie: PRO und KO BG SCHRADER, J. et al., A BH SCHRADER, JOACHIM Survivors, Stroke, July 2 BI SCHRADER, J., Intervie	BF Hypertonie: PRO und KONTRA Fixe  BG SCHRADER, J. et al., ACE-Hernmer,  BH SCHRADER, JOACHIM. et al., The Survivors, Stroke, July 2003, pp 1699  BI SCHRADER, J., Interview mit Studie	BG SCHRADER, J., Interview mit Studienleiter Prof. Joachim Schrader:    Examiner Name   Examiner Name   Schrader:				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English tanguage Translation is attached.

Date

Considered

Examiner

Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.